Ardana: A Global Company Based in Edinburgh
Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.
Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.
Ardana was established to commercialize research undertaken at the Medical Research Council's Human Reproductive Sciences Unit (HRSU). The HRSU has been at the forefront of research in the human reproductive system for the last 30 years, and the unit is one of only four academic centers of excellence in human reproductive biology in the world.
Since its inception, Ardana has raised £34.6 million in three funding rounds. Ardana investors include Techno Venture Management, Merlin Biosciences, MVM, ABN-AMRO Capital, 3i, ISIS Equity Partners, Scottish Widows Investment Partnership, Mitsubishi, and Green Highlander.
Ardana is a global company in the truest sense of the word. The company, which is based in the center of Edinburgh's stunning new town, collaborates with companies across the globe. The excellence of the science undertaken at the HRSU and Ardana's close links with other local centers of excellence, such as the University of Edinburgh Department of Obstetrics and Gynecology, make Edinburgh a strong location for the company.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypotheses is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The author highlights the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
